Breaking News, Collaborations & Alliances

Scancell Licenses CRT Antibody

Scancell Holdings and Cancer Research Technology, Ltd. (CRT) have signed an agreement under which Scancell has been granted a license to use a human antibody known as 105AD7.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Scancell Holdings and Cancer Research Technology, Ltd. (CRT) have signed an agreement under which Scancell has been granted a license to use a human antibody known as 105AD7. The antibody has previously been evaluated in clinical trials for osteosarcoma. Scancell’s worldwide license will be aimed at the development of new ImmunoBody vaccines for any immunotherapy indication. The license is limited to the use of the antibody as a framework for future vaccines. Under the agreement, CRT will rec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters